Ушбу иш иқтибос қилган ишлар

199 та иш

Иш: Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

1. Anti-BCMA Dual Epitope-Binding CAR-Marrow Infiltrating Lymphocytes (MILs) Could Offer a Potent Innovative Immunotherapeutic Tool Against Multiple Myeloma

   Manh-Cuong Vo, Sunghoon Jung, Van‐Tan Nguyen +6

   Мақола20232 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.102952

2. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial

   Stephen Bagley, Zev A. Binder, Lamia Lamrani +32

   Мақола20242 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.102955

3. CAR T therapies in multiple myeloma: unleashing the future

   Mohsen Sheykhhasan, Amirhossein Ahmadieh-Yazdi, Rosario Vicidomini +7

   Мақола20242 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.102958

4. Development of NK cell-based cancer immunotherapies through receptor engineering

   Audrey Page, Nicolas Chuvin, Jenny Valladeau‐Guilemond +1

   Мақола20242 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.102960

5. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results

   Stephen Bagley, Meghan Logun, Joseph A. Fraietta +30

   Мақола20242 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.102963

6. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets

   Shaosen Zhang, Xinyi Xiao, Yonglin Yi +5

   Шарҳ мақола20242 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.102975

7. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy

   X. Xia, Zongxin Yang, Qisi Lu +6

   Шарҳ мақола20242 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.102984

8. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial

   Changsong Qi, Chang Liu, Zhi Peng +31

   Мақола20252 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.103004

9. In vivo CAR T cell generation to treat cancer and autoimmune disease

   Theresa Hunter, Yanjie Bao, Yan Zhang +37

   Мақола20252 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.103005

10. Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives

    Muqadas Shahzadi, Hamad Rafique, Ahmad Waheed +4

    Шарҳ мақолаCAR-T cell therapy researchTherapeutic Advances in Vaccines and Immunotherapy20241 иқтибос

    ABIABI:AkademIndex/openalex/2024.review-article.000014

11. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102819

12. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102820

13. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102822

14. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102824

15. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102825

16. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102826

17. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102827

18. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102828

19. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102830

20. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102834

21. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102836

22. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102837

23. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102838

24. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102839

25. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102841